Evidence map›Paper›PMID 29998365›Full record

ArticleInvestigational new drugs2019

Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.

Christian Dittrich, Robert Königsberg, Martina Mittlböck, Klaus Geissler, Azra Sahmanovic-Hrgovcic, Johannes Pleiner-Duxneuner, Martin Czejka, Philipp Buchner

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Christian DittrichApplied Cancer Research - Institution for Translational Research Vienna (ACR-ITR VIEnna), Bernardgasse 24/2, 1070, Vienna, Austria. ch.dittrich@chello.at.
Robert KönigsbergApplied Cancer Research - Institution for Translational Research Vienna (ACR-ITR VIEnna), Bernardgasse 24/2, 1070, Vienna, Austria.
Martina MittlböckSection for Clinical Biometrics, Centre for Medical Statistics, Informatics, and Intelligent Systems (CeMSIIS), Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Klaus Geissler5th Medical Department with Oncology and Palliative Medicine, Hietzing Hospital, Wolkersbergenstrasse 1, 1130, Vienna, Austria.
Azra Sahmanovic-HrgovcicDivision of Clinical Pharmacy, Department of Pharmaceutical Chemistry, Centre of Pharmacy, University of Vienna, Althanstrasse 14, 1090, Vienna, Austria.
Johannes Pleiner-DuxneunerMedical and Regulatory Affairs, Roche Austria, Engelhorngasse 3, 1211, Vienna, Austria.
Martin CzejkaDivision of Clinical Pharmacy, Department of Pharmaceutical Chemistry, Centre of Pharmacy, University of Vienna, Althanstrasse 14, 1090, Vienna, Austria.
Philipp BuchnerDivision of Clinical Pharmacy, Department of Pharmaceutical Chemistry, Centre of Pharmacy, University of Vienna, Althanstrasse 14, 1090, Vienna, Austria.
University of Vienna · ATLudwig Boltzmann Institute for Cancer Research · ATKlinik Hietzing · ATMedical University of Vienna · ATRoche (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Purpose of this phase Ib trial was to establish the maximum tolerable dose (MTD) of capecitabine and to escalate the dosages of erlotinib and bevacizumab to determine the recommended phase II dose (RP2D) in patients with advanced/metastatic pancreatic adenocarcinoma not pretreated for metastatic disease. Methods Starting doses were capecitabine 500 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCapecitabineCohort StudiesErlotinib HydrochlorideFemaleFollow-Up StudiesHumansMaleMaximum Tolerated DoseMiddle AgedPancreatic NeoplasmsSurvival RateTissue DistributionTreatment OutcomeBevacizumabCapecitabineErlotinib HydrochlorideBevacizumabCapecitabineErlotinibLocally advanced / metastatic pancreatic adenocarcinomaPharmacokineticsPhase Ib

Identifiers

PMID29998365
OpenAlexW2838894529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.